Ucbbiopharma Srl

Sanofi

Ucb Biopharma Sprl

Teresa De Haro Garcia

Zhaoning Zhu

Malcolm Maccoss

Daniel Christopher Brookings

James Andrew Johnson

Martin Clive Hutchings

Jag Paul Heer

Jean Keyaerts

Yann Foricher

Sophie Jadot

Mengyang Xuan

Laurent Schio

Matthew Duncan Selby

Bruno Filoche-Romme

Richard David Taylor

Joanna Rachel Quincey

Martin Alexander Lowe

Mark Daniel Calmiano

Michael Alan Shaw

Michael Deligny

Dominique Louis Leon Swinnen

Yves Evrard

Helen Tracey Horsley

Malcolm Mac Coss

Michael Louis Robert Deligny

Dominique Louis Léon Swinnen

Trevor Morgan

Rebecca Louise Charlton

Lloyd Malcolm King

Michaël Louis Robert Deligny

Dominique Louis Swinnen

A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

Fused pentacyclic imidazole derivatives

The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of theparasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria. 

Antimalarial hexahydropyrimidine analogues

A series of 2-imino-6-methyltetrahydropyrimidin-4(1H)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors

Disclosed herein are compounds of formula (I) and pharmaceutically acceptable salt thereof, wherein variables X, R, R, and Rare defined herein. These compounds are potent modulators of human TNF&#x3b1; activity and, accordingly, of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Fused pentacyclic imidazole derivatives as modulators of TNF activity

A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

Disclosed are substituted fused hexacyclic benzimidazole derivatives of Formula (I) wherein the variables A, B, D, X, M, Q, n, p, q, Z, E, R, and Rare defined herein. These compounds are potent modulators of human TNF&#x3b1; activity and of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Fused hexacyclic imidazole derivatives as modulators of TNF activity

A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria. 

Iminothiadiazinane dioxide derivatives as plasmepsin V inhibitors

Growing community of inventors

Slough, United Kingdom

Teresa De Haro Garcia